Evidence map›Paper›PMID 25967290›Full record

Trial reportBMC veterinary research2015

Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.

Kathrin Mählmann, Karsten Feige, Christiane Juhls, Anne Endmann, Hans-Joachim Schuberth, Detlef Oswald, Mareu Hellige, Marcus Doherr, Jessika-M V Cavalleri

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in BMC veterinary research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Equine Melanocytic Tumors: A Narrative Review.Animals : an open access journal from MDPI · 2023
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kathrin MählmannClinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. kathrin.maehlmann@vetsuisse.unibe.ch.
Karsten FeigeClinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. karsten.feige@tiho-hannover.de.
Christiane JuhlsMologen AG, Berlin, Germany. juhls@mologen.com.
Anne EndmannMologen AG, Berlin, Germany. endmann@mologen.com.
Hans-Joachim SchuberthImmunology Unit, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. hans-joachim.schuberth@tiho-hannover.de.
Detlef OswaldMologen AG, Berlin, Germany. Oswald@mologen.com.
Mareu HelligeClinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. maren.hellige@tiho-hannover.de.
Marcus DoherrInstitute for Veterinary Epidemiology and Biostatistics, Free University of Berlin, Berlin, Germany. marcus.doherr@fu-berlin.de.
Jessika-M V CavalleriClinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. jessika.cavalleri@tiho-hannover.de.
University of Veterinary Medicine Hannover, Foundation · DEMologen (Germany) · DEFreie Universität Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEquine melanoma has a high incidence in grey horses. Xenogenic DNA vaccination may represent a promising therapeutic approach against equine melanoma as it successfully induced an immunological response in other species suffering from melanoma and in healthy horses. In a clinical study, twenty-seven, grey, melanoma-bearing, horses were assigned to three groups (n = 9) and vaccinated on days 1, 22, and 78 with DNA vectors encoding for equine (eq) IL-12 and IL-18 alone or in combination with either human glycoprotein (hgp) 100 or human tyrosinase (htyr). Horses were vaccinated intramuscularly, and one selected melanoma was locally treated by intradermal peritumoral injection. Prior to each injection and on day 120, the sizes of up to nine melanoma lesions per horse were measured by caliper and ultrasound. Specific serum antibodies against hgp100 and htyr were measured using cell based flow-cytometric assays. An Analysis of Variance (ANOVA) for repeated measurements was performed to identify statistically significant influences on the relative tumor volume. For post-hoc testing a Tukey-Kramer Multiple-Comparison Test was performed to compare the relative volumes on the different examination days. An ANOVA for repeated measurements was performed to analyse changes in body temperature over time. A one-way ANOVA was used to evaluate differences in body temperature between the groups. A p-value < 0.05 was considered significant for all statistical tests applied.

resultsIn all groups, the relative tumor volume decreased significantly to 79.1 ± 26.91% by day 120 (p < 0.0001, Tukey-Kramer Multiple-Comparison Test). Affiliation to treatment group, local treatment and examination modality had no significant influence on the results (ANOVA for repeated measurements). Neither a cellular nor a humoral immune response directed against htyr or hgp100 was detected. Horses had an increased body temperature on the day after vaccination.

conclusionsThis is the first clinical report on a systemic effect against equine melanoma following treatment with DNA vectors encoding eqIL12 and eqIL18 and formulated with a transfection reagent. Addition of DNA vectors encoding hgp100 respectively htyr did not potentiate this effect.

Indexed as

AnimalsAntibodiesCancer VaccinesDNA, NeoplasmFemaleGenetic VectorsHorse DiseasesHorsesInjections, IntralesionalInjections, IntramuscularMaleMelanomaNeoplasm ProteinsTransfectionVaccines, DNAAntibodiesCancer VaccinesDNA, NeoplasmNeoplasm ProteinsVaccines, DNA

Identifiers

PMID25967290
PMCPMC4429833
OpenAlexW1500356886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.